Joseph Ruiz, PhD

Chief Operating officer

Dr. Joseph Ruiz, President, has over 25 years experience as an investigator in academia and industry in embryonic and adult stem cell biology, genome engineering, hepatic cell biology, cell transplantation, and histotechnology. He frequently serves as a reviewer and chair for NIH Small Business Scientific Review Groups.  Dr. Ruiz’s background of holding positions in both academia and the biotech industry has given him a unique perspective on the importance of developing a comprehensive research plan while also driving research toward clinical or commercial applications. He obtained his PhD  at UC San Diego and completed post-doctoral work at Columbia and Harvard Universities. Dr. Ruiz has held faculty positions at the Indiana School of Medicine and at the Wistar Institute, and has directed scientific development at several biotech startup companies. 


.

Peter Sazani, PhD

Chief Development Officer

Dr Sazani brings 16 years research and development leadership experience, and has a passion for tackling rare genetic diseases. Prior to joining Enzerna, Dr Sazani was the head of patient advocacy and medical affairs at Marathon Pharmaceuticals (Now PTC Therapeutics), helping guide the Duchenne community through the approval of Emflaza (deflazacort). Prior to Marathon, Dr Sazani was Executive Director of Pre-clinical development and Medical Affairs at Sarepta Therapeutics. While there, Dr Sazani conducted and oversaw the research, and subsequently all pre-clinical, clinical pharmacology and medical affairs activities related to Exondys (eteplirsen). Dr Sazani was also heavily involved in negotiations with FDA regarding eteplirsen. Dr Sazani joined Sarepta through the 2007 acquisition of Ercole Biotech, a company founded to commercialize Exon Skipping technology. Prior to that, Dr Sazani was a post doctoral fellow at Harvard Medical School; he received his PhD in Pharmacology from The University of North Carolina at Chapel Hill.